With the data obtained in this study, we believe that ACE inhibitors, AT1 receptor blockers, or AT2 receptor agonists will become an essential target for treating type 1 diabetes and other diseases associated with hypercorticoidism in the future. Here, AGTR1 is linked to type 1 diabetes mellitus.